{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:59:32Z","timestamp":1793055572857,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41417-026-01055-2","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:45:47Z","timestamp":1783723547000},"page":"944-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["LD\u2013associated signatures identified by perilipin-based proximity labeling proteomics reveal GNA14 as a therapeutic and prognostic target in renal cell carcinoma"],"prefix":"10.1038","volume":"33","author":[{"given":"Yuankang","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjian","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6042-2879","authenticated-orcid":false,"given":"Yaqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1722-7485","authenticated-orcid":false,"given":"Dan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-7222","authenticated-orcid":false,"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2025.109155","volume":"274","author":"M Mohamad","year":"2026","unstructured":"Mohamad M, Ponzio F, Di Cataldo S, Ambrosetti D, Descombes X. Renal cell carcinoma subtyping: learning from multi-resolution localization. Comput Methods Prog Biomed. 2026;274:109155.","journal-title":"Comput Methods Prog Biomed"},{"key":"1055_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s43018-025-00942-1","volume":"6","author":"MB McKinnon","year":"2025","unstructured":"McKinnon MB, Rini BI, Haake SM. Biomarker-informed care for patients with renal cell carcinoma. Nat Cancer. 2025;6:573\u201383.","journal-title":"Nat Cancer"},{"key":"1055_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","volume":"87","author":"A Bex","year":"2025","unstructured":"Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2025 update. Eur Urol. 2025;87:683\u201396.","journal-title":"Eur Urol"},{"key":"1055_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2025.01.014","volume":"87","author":"J Bedke","year":"2025","unstructured":"Bedke J, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma. Eur Urol. 2025;87:491\u20136.","journal-title":"Eur Urol"},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(25)00032-4","volume":"26","author":"T Powles","year":"2025","unstructured":"Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, et al. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26:491\u2013502.","journal-title":"Lancet Oncol"},{"key":"1055_CR6","doi-asserted-by":"crossref","unstructured":"Alnukhali M, Fornoni A, Pollack A, Ahmad A. Lipid dysregulation in renal cancer: drivers of tumor growth and determinants of treatment-induced toxicity. Semin Cancer Biol. 2026;119:54\u201364.","DOI":"10.1016\/j.semcancer.2025.12.010"},{"key":"1055_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09664-x","volume":"15","author":"O Fresnedo","year":"2025","unstructured":"Fresnedo O, Lopez-Gomez JA, Ceniceros C, Larrinaga G, Saiz A, Mosteiro L, et al. Adaptations of lipid metabolism in low-grade clear cell renal cell carcinoma are linked to cholesteryl ester accumulation. Sci Rep. 2025;15:24762.","journal-title":"Sci Rep"},{"key":"1055_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102513","volume":"61","author":"J Simeth","year":"2025","unstructured":"Simeth J, Engelmann S, Mayr R, Kaelble S, Weber F, Pichler R, et al. Lipid metabolism of clear cell renal cell carcinoma predicts survival and affects intratumoral CD8 T cells. Transl Oncol. 2025;61:102513.","journal-title":"Transl Oncol"},{"key":"1055_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41392-025-02496-1","volume":"10","author":"N Yue","year":"2025","unstructured":"Yue N, Zhao H, Zhang Y, Gu J, Qi J, Wen J, et al. Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism. Signal Transduct Target Ther. 2025;10:398.","journal-title":"Signal Transduct Target Ther"},{"key":"1055_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00109-025-02635-9","volume":"104","author":"Z Wang","year":"2026","unstructured":"Wang Z, Kong D, Wei W. The role of ferroptosis in renal cell carcinoma: molecular mechanisms and therapeutic implications. J Mol Med. 2026;104:22.","journal-title":"J Mol Med"},{"key":"1055_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02457-w","volume":"24","author":"Q Deng","year":"2025","unstructured":"Deng Q, Ji Y, Liu J, Wen T. Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting. Mol Cancer. 2025;24:236.","journal-title":"Mol Cancer"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/carcin\/bgab098","volume":"42","author":"C Xu","year":"2021","unstructured":"Xu C, Li YM, Sun B, Zhong FJ, Yang LY. GNA14\u2019s interaction with RACK1 inhibits hepatocellular carcinoma progression through reducing MAPK\/JNK and PI3K\/AKT signaling pathway. Carcinogenesis. 2021;42:1357\u201369.","journal-title":"Carcinogenesis"},{"key":"1055_CR13","first-page":"165","volume":"20","author":"T Yu","year":"2020","unstructured":"Yu T, Lu S, Xie W. Downregulation of GNA14 in hepatocellular carcinoma indicates an unfavorable prognosis. Oncol Lett. 2020;20:165\u201372.","journal-title":"Oncol Lett"},{"key":"1055_CR14","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.7150\/thno.48739","volume":"11","author":"G Song","year":"2021","unstructured":"Song G, Zhu X, Xuan Z, Zhao L, Dong H, Chen J, et al. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma. Theranostics. 2021;11:2318\u201333.","journal-title":"Theranostics"},{"key":"1055_CR15","doi-asserted-by":"crossref","unstructured":"Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.","DOI":"10.1126\/science.aan2507"},{"key":"1055_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03184-4","volume":"43","author":"J Ma","year":"2025","unstructured":"Ma J, Feng Y, Dong Y, Yue D, Wang Y. PLIN3: a multifaceted regulator of lipid droplet dynamics and disease pathogenesis. Med Oncol. 2025;43:65.","journal-title":"Med Oncol"},{"key":"1055_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30579","volume":"125","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen S, Weiskirchen R. Perilipins: A family of five fat-droplet storing proteins that play a significant role in fat homeostasis. J Cell Biochem. 2024;125:e30579.","journal-title":"J Cell Biochem"},{"key":"1055_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45:860\u20137.","journal-title":"Nat Genet"},{"key":"1055_CR19","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","volume":"21","author":"B Beuselinck","year":"2015","unstructured":"Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin Cancer Res. 2015;21:1329\u201339.","journal-title":"Clin Cancer Res"},{"key":"1055_CR20","doi-asserted-by":"publisher","first-page":"E693","DOI":"10.1002\/ijc.27419","volume":"131","author":"D Wuttig","year":"2012","unstructured":"Wuttig D, Zastrow S, Fussel S, Toma MI, Meinhardt M, Kalman K, et al. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer. 2012;131:E693\u2013704.","journal-title":"Int J Cancer"},{"key":"1055_CR21","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"1055_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"1055_CR23","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133.","journal-title":"Bioinformatics"},{"key":"1055_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0730-1","volume":"11","author":"S Engebretsen","year":"2019","unstructured":"Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin Epigenet. 2019;11:123.","journal-title":"Clin Epigenet"},{"key":"1055_CR25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","volume":"56","author":"PJ Heagerty","year":"2000","unstructured":"Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56:337\u201344.","journal-title":"Biometrics"},{"key":"1055_CR26","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"1055_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2024.100910","volume":"4","author":"D Zeng","year":"2024","unstructured":"Zeng D, Fang Y, Qiu W, Luo P, Wang S, Shen R, et al. Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0. Cell Rep Methods. 2024;4:100910.","journal-title":"Cell Rep Methods"},{"key":"1055_CR28","doi-asserted-by":"crossref","unstructured":"Hu FF, Liu CJ, Liu LL, Zhang Q, Guo AY. Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. Brief Bioinform. 2021;22:bbaa176.","DOI":"10.1093\/bib\/bbaa176"},{"key":"1055_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nchembio.1986","volume":"12","author":"MG Rees","year":"2016","unstructured":"Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol. 2016;12:109\u201316.","journal-title":"Nat Chem Biol"},{"key":"1055_CR30","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","volume":"5","author":"B Seashore-Ludlow","year":"2015","unstructured":"Seashore-Ludlow B, Rees MG, Cheah JH, Cokol M, Price EV, Coletti ME, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 2015;5:1210\u201323.","journal-title":"Cancer Discov"},{"key":"1055_CR31","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, Price EV, Liu K, Schaefer GI, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361.","journal-title":"Cell"},{"key":"1055_CR32","doi-asserted-by":"crossref","unstructured":"Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22:bbab260.","DOI":"10.1093\/bib\/bbab260"},{"key":"1055_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630:493\u2013500.","journal-title":"Nature"},{"key":"1055_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-0716-3441-7_5","volume":"2714","author":"A Singh","year":"2024","unstructured":"Singh A, Copeland MM, Kundrotas PJ, Vakser IA. GRAMM Web server for protein docking. Methods Mol Biol. 2024;2714:101\u201312.","journal-title":"Methods Mol Biol"},{"key":"1055_CR35","doi-asserted-by":"crossref","unstructured":"Najt CP, Devarajan M, Mashek DG. Perilipins at a glance. J Cell Sci. 2022;135:jcs259501.","DOI":"10.1242\/jcs.259501"},{"key":"1055_CR36","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10:1808\u201325.","journal-title":"Cancer Discov"},{"key":"1055_CR37","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"1055_CR38","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1158\/0008-5472.CAN-24-4962","volume":"85","author":"J Shi","year":"2025","unstructured":"Shi J, Huang S, Zhou Y, Zheng G, Zhang Z, Fan X, et al. SPP1+ neutrophils mediate resistance to immune checkpoint blockade in BAP1-inactivated tumors. Cancer Res. 2025;85:4433\u201349.","journal-title":"Cancer Res"},{"key":"1055_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1151651","volume":"14","author":"ZT Liang","year":"2023","unstructured":"Liang ZT, Li JK, Li J, Tang H, Guo CF, Zhang HQ. PECAM1 plays a role in the pathogenesis and treatment of bone metastases. Front Genet. 2023;14:1151651.","journal-title":"Front Genet"},{"key":"1055_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04536-2","volume":"21","author":"X Tang","year":"2023","unstructured":"Tang X, Huang J, Jiang Y, Qiu J, Li T, Li W, et al. Intercellular adhesion molecule 2 as a novel prospective tumor suppressor induced by ERG promotes ubiquitination-mediated radixin degradation to inhibit gastric cancer tumorigenicity and metastasis. J Transl Med. 2023;21:670.","journal-title":"J Transl Med"},{"key":"1055_CR41","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1055_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","volume":"82","author":"L Bukavina","year":"2022","unstructured":"Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82:529\u201342.","journal-title":"Eur Urol"},{"key":"1055_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/ndt\/gfae036","volume":"39","author":"L Cirillo","year":"2024","unstructured":"Cirillo L, Innocenti S, Becherucci F. Global epidemiology of kidney cancer. Nephrol Dial Transpl. 2024;39:920\u20138.","journal-title":"Nephrol Dial Transpl"},{"key":"1055_CR44","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 2021;385:683\u201394.","journal-title":"N Engl J Med"},{"key":"1055_CR45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384:829\u201341.","journal-title":"N Engl J Med"},{"key":"1055_CR46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289\u20131300.","journal-title":"N Engl J Med"},{"key":"1055_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02059-y","volume":"23","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Jin Y, Zhou J, Chen F, Chen M, Gao Z, et al. PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Mol Cancer. 2024;23:146.","journal-title":"Mol Cancer"},{"key":"1055_CR48","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41416-024-02747-y","volume":"131","author":"S Wang","year":"2024","unstructured":"Wang S, Wang K, Yue D, Yang X, Pan X, Kong F, et al. MT1G induces lipid droplet accumulation through modulation of H3K14 trimethylation accelerating clear cell renal cell carcinoma progression. Br J Cancer. 2024;131:641\u201354.","journal-title":"Br J Cancer"},{"key":"1055_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101712","volume":"13","author":"X Xiang","year":"2026","unstructured":"Xiang X, Chen J, Che L. Emerging roles and therapeutic implications of lipid droplet protein perilipin 2 in liver disease. Genes Dis. 2026;13:101712.","journal-title":"Genes Dis"},{"key":"1055_CR50","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41418-022-01018-8","volume":"29","author":"Y Wu","year":"2022","unstructured":"Wu Y, Chen K, Li L, Hao Z, Wang T, Liu Y, et al. Plin2-mediated lipid droplet mobilization accelerates exit from pluripotency by lipidomic remodeling and histone acetylation. Cell Death Differ. 2022;29:2316\u201331.","journal-title":"Cell Death Differ"},{"key":"1055_CR51","doi-asserted-by":"crossref","unstructured":"Stephens IO, Johnson LA. Knockout of perilipin-2 in microglia alters lipid droplet accumulation and response to alzheimer\u2019s disease stimuli. Cells. 2025;14:1783.","DOI":"10.3390\/cells14221783"},{"key":"1055_CR52","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12672-024-01069-y","volume":"15","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, He J, Zuo B, He Y. Role of lipid metabolism in hepatocellular carcinoma. Discov Oncol. 2024;15:206.","journal-title":"Discov Oncol"},{"key":"1055_CR53","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1681\/ASN.2015060621","volume":"27","author":"H Khalili","year":"2016","unstructured":"Khalili H, Sull A, Sarin S, Boivin FJ, Halabi R, Svajger B, et al. Developmental origins for kidney disease due to Shroom3 deficiency. J Am Soc Nephrol. 2016;27:2965\u201373.","journal-title":"J Am Soc Nephrol"},{"key":"1055_CR54","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ekir.2025.02.018","volume":"10","author":"D Ghasemi-Semeskandeh","year":"2025","unstructured":"Ghasemi-Semeskandeh D, Konig E, Foco L, Dordevic N, Gogele M, Rainer J, et al. Clinical and metabolic signatures of FAM47E-SHROOM3 haplotypes in a general population sample. Kidney Int Rep. 2025;10:1495\u2013508.","journal-title":"Kidney Int Rep"},{"key":"1055_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2024.1407265","volume":"11","author":"Z Cheng","year":"2024","unstructured":"Cheng Z, Liu B, Liu X. Circadian gene signatures in the progression of obesity based on machine learning and Mendelian randomization analysis. Front Nutr. 2024;11:1407265.","journal-title":"Front Nutr"},{"key":"1055_CR56","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.ajpath.2024.08.003","volume":"194","author":"M Leya","year":"2024","unstructured":"Leya M, Jeong H, Yang D, Ton Nu Bao TH, Pandeya PR, Oh SI, et al. Hepatocyte-specific casein kinase 1 epsilon ablation ameliorates metabolic dysfunction-associated steatohepatitis by up-regulating tumor necrosis factor receptor-associated factor 3 in mice. Am J Pathol. 2024;194:2106\u201327.","journal-title":"Am J Pathol"},{"key":"1055_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1402351","volume":"14","author":"Z Chen","year":"2024","unstructured":"Chen Z, Zhang X. The role of metabolic reprogramming in kidney cancer. Front Oncol. 2024;14:1402351.","journal-title":"Front Oncol"},{"key":"1055_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105070","volume":"103","author":"S Zhang","year":"2024","unstructured":"Zhang S, Fang T, He Y, Feng W, Yu Z, Zheng Y, et al. VHL mutation drives human clear cell renal cell carcinoma progression through PI3K\/AKT-dependent cholesteryl ester accumulation. EBioMedicine. 2024;103:105070.","journal-title":"EBioMedicine"},{"key":"1055_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1078759","volume":"11","author":"K Li","year":"2023","unstructured":"Li K, Zhu Y, Cheng J, Li A, Liu Y, Yang X, et al. A novel lipid metabolism gene signature for clear cell renal cell carcinoma using integrated bioinformatics analysis. Front Cell Dev Biol. 2023;11:1078759.","journal-title":"Front Cell Dev Biol"},{"key":"1055_CR60","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/ajcp\/aqaa176","volume":"155","author":"AJ Gallan","year":"2021","unstructured":"Gallan AJ, Parilla M, Segal J, Ritterhouse L, Antic T. BAP1-mutated clear cell renal cell carcinoma. Am J Clin Pathol. 2021;155:718\u201328.","journal-title":"Am J Clin Pathol"},{"key":"1055_CR61","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181\u201392.","journal-title":"Nat Cell Biol"},{"key":"1055_CR62","doi-asserted-by":"publisher","first-page":"1536845","DOI":"10.1080\/23723556.2018.1536845","volume":"6","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhuang L, Gan B. BAP1 suppresses tumor development by inducing ferroptosis upon SLC7A11 repression. Mol Cell Oncol. 2019;6:1536845.","journal-title":"Mol Cell Oncol"},{"key":"1055_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jare.2024.04.032","volume":"70","author":"Z Wei","year":"2025","unstructured":"Wei Z, Ye Y, Liu C, Wang Q, Zhang Y, Chen K, et al. MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma. J Adv Res. 2025;70:287\u2013305.","journal-title":"J Adv Res"},{"key":"1055_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105732","volume":"170","author":"Y He","year":"2021","unstructured":"He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, et al. New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Pharmacol Res. 2021;170:105732.","journal-title":"Pharmacol Res"},{"key":"1055_CR65","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 2006;12:7271\u20138.","journal-title":"Clin Cancer Res"},{"key":"1055_CR66","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ejca.2011.12.022","volume":"48","author":"P Mulders","year":"2012","unstructured":"Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012;48:527\u201337.","journal-title":"Eur J Cancer"},{"key":"1055_CR67","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/annonc\/mdw014","volume":"27","author":"T Powles","year":"2016","unstructured":"Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, et al. A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Ann Oncol. 2016;27:880\u20136.","journal-title":"Ann Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01055-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:03:29Z","timestamp":1787339009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01055-2","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Ethics Committee of Tianjin Medical University Second Hospital (Approval No. KY2025K076) and conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}